New Gilead CEO's Game Plan to Maintain HCV Dominance
Gilead Sciences, Inc. (NASDAQ:GILD) is set to maintain its undisputed lead in the fast expanding market of Hepatitis C drugs. John Milligan, the new CEO Gilead, has brought about a much-needed change to boost the stagnating sales growth of the company's HCV drugs franchise.
Dr. Milligan was promoted as the CEO in January 2016 after John Martin stepped down from his pilot position, which he held for 20 years. Dr Milligan has been affiliated with the biotech for nearly 26 years as a research scientist, and has seen its transformation from a small company into one with remarkable growth. He has now been assigned the task of searching for new growth options..
Dr. Milligan was promoted as the CEO in January 2016 after John Martin stepped down from his pilot position, which he held for 20 years. Dr Milligan has been affiliated with the biotech for nearly 26 years as a research scientist, and has seen its transformation from a small company into one with remarkable growth. He has now been assigned the task of searching for new growth options..